Human regulatory T-cell development is dictated by Interleukin-2 and -15 expressed in a non-overlapping pattern in the thymus

Journal of Autoimmunity

Volumn 56, Issue , 2015, Pages 98-110

  Caramalho, Iris ^a   Nunes Silva, Vânia ^a   Pires, Ana R ^a   Mota, Catarina ^a   Pinto, Ana I ^a   Nunes Cabaço, Helena ^a   Foxall, Russell B ^a   Sousa, Ana E ^a  

^a UNIVERSITY OF LISBON   (Portugal)

Author keywords

Common gamma chain cytokines; FOXP3; Human T cell development; Immune tolerance; Regulatory T cells

Indexed keywords

INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 4; INTERLEUKIN 7; TRANSCRIPTION FACTOR FOXP3; CYTOKINE; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN;

ARTICLE; B LYMPHOCYTE; CELL MATURATION; CELL SURVIVAL; CHILD; FUNCTIONAL STATUS; GAIN OF FUNCTION MUTATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LOSS OF FUNCTION MUTATION; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MONOCYTE; NEWBORN; ORGAN CULTURE; PHENOTYPE; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; THYMUS; CELL DIFFERENTIATION; CYTOLOGY; GENE EXPRESSION; GENETICS; IMMUNOLOGY; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; METABOLISM; THYMOCYTE;

CELL DIFFERENTIATION; CELL SURVIVAL; CYTOKINES; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION; HUMANS; IMMUNOPHENOTYPING; INTERLEUKIN-15; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; PHENOTYPE; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY; THYMOCYTES; THYMUS GLAND;

EID: 84920149783     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2014.11.002     Document Type: Article

References (55)

1. Sakaguchi S., Miyara M., Costantino C.M., Hafler D.A. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 2010, 10:490-500.
2. Josefowicz S.Z., Lu L.F., Rudensky A.Y. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol 2012, 30:531-564.
3. Lee H.M., Bautista J.L., Hsieh C.S. Thymic and peripheral differentiation of regulatory T cells. Adv Immunol 2011, 112:25-71.
4. Buckner J.H. Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases. Nat Rev Immunol 2010, 10:849-859.
5. von Boehmer H., Daniel C. Therapeutic opportunities for manipulating T(reg) cells in autoimmunity and cancer. Nat Rev Drug Discov 2013, 12:51-63.
6. Blom B., Spits H. Development of human lymphoid cells. Annu Rev Immunol 2006, 24:287-320.
7. Darrasse-Jeze G., Marodon G., Salomon B.L., Catala M., Klatzmann D. Ontogeny of CD4+CD25+ regulatory/suppressor T cells in human fetuses. Blood 2005, 105:4715-4721.
8. Cupedo T., Nagasawa M., Weijer K., Blom B., Spits H. Development and activation of regulatory T cells in the human fetus. Eur J Immunol 2005, 35:383-390.
9. Nunes-Cabaco H., Ribot J.C., Caramalho I., Serra-Caetano A., Silva-Santos B., Sousa A.E. Foxp3 induction in human and murine thymus precedes the CD4+ CD8+ stage but requires early T-cell receptor expression. Immunol Cell Biol 2010, 88:523-528.
10. Martin-Gayo E., Sierra-Filardi E., Corbi A.L., Toribio M.L. Plasmacytoid dendritic cells resident in human thymus drive natural Treg cell development. Blood 2010, 115:5366-5375.
11. Nunes-Cabaco H., Caramalho I., Sepulveda N., Sousa A.E. Differentiation of human thymic regulatory T cells at the double positive stage. Eur J Immunol 2011, 41:3604-3614.
12. Watanabe N., Wang Y.H., Lee H.K., Ito T., Cao W., Liu Y.J. Hassall's corpuscles instruct dendritic cells to induce CD4+CD25+ regulatory T cells in human thymus. Nature 2005, 436:1181-1185.
13. Hanabuchi S., Ito T., Park W.R., Watanabe N., Shaw J.L., Roman E., et al. Thymic stromal lymphopoietin-activated plasmacytoid dendritic cells induce the generation of FOXP3+ regulatory T cells in human thymus. JImmunol 2010, 184:2999-3007.
14. Michaelsson J., Mold J.E., McCune J.M., Nixon D.F. Regulation of T cell responses in the developing human fetus. JImmunol 2006, 176:5741-5748.
15. Mold J.E., Michaelsson J., Burt T.D., Muench M.O., Beckerman K.P., Busch M.P., et al. Maternal alloantigens promote the development of tolerogenic fetal regulatory T cells in utero. Science 2008, 322:1562-1565.
16. Cheng G., Yu A., Malek T.R. T-cell tolerance and the multi-functional role of IL-2R signaling in T-regulatory cells. Immunol Rev 2011, 241:63-76.
17. Yamane H., Paul W.E. Cytokines of the gamma(c) family control CD4+ T cell differentiation and function. Nat Immunol 2012, 13:1037-1044.
18. Weiss L., Letimier F.A., Carriere M., Maiella S., Donkova-Petrini V., Targat B., et al. Invivo expansion of naive and activated CD4+CD25+FOXP3+ regulatory T cell populations in interleukin-2-treated HIV patients. Proc Natl Acad Sci U S A 2010, 107:10632-10637.
19. Beyer M., Schumak B., Weihrauch M.R., Andres B., Giese T., Endl E., et al. Invivo expansion of naive CD4+ CD25(high) FOXP3+ regulatory T cells in patients with colorectal carcinoma after IL-2 administration. PLoS One 2012, 7:e30422.
20. Matsuoka K., Koreth J., Kim H.T., Bascug G., McDonough S., Kawano Y., et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med 2013, 5:179ra43.
21. Young C.D., Angel J.B. Optimization of culture and storage conditions for an invitro system to evaluate thymocyte phenotype and function. JImmunol Methods 2006, 312:157-166.
22. Paiva R.S., Lino A.C., Bergman M.L., Caramalho I., Sousa A.E., Zelenay S., et al. Recent thymic emigrants are the preferential precursors of regulatory T cells differentiated in the periphery. Proc Natl Acad Sci U S A 2013, 110:6494-6499.
23. Yeoman H., Clark D.R., DeLuca D. Development of CD4 and CD8 single positive T cells in human thymus organ culture: IL-7 promotes human T cell production by supporting immature T cells. Dev Comp Immunol 1996, 20:241-263.
24. Okamoto Y., Douek D.C., McFarland R.D., Koup R.A. Effects of exogenous interleukin-7 on human thymus function. Blood 2002, 99:2851-2858.
25. Boyman O., Kovar M., Rubinstein M.P., Surh C.D., Sprent J. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 2006, 311:1924-1927.
26. Dubois S., Mariner J., Waldmann T.A., Tagaya Y. IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. Immunity 2002, 17:537-547.
27. Fontenot J.D., Rasmussen J.P., Gavin M.A., Rudensky A.Y. Afunction for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 2005, 6:1142-1151.
28. D'Cruz L.M., Klein L. Development and function of agonist-induced CD25+Foxp3+ regulatory T cells in the absence of interleukin 2 signaling. Nat Immunol 2005, 6:1152-1159.
29. Burchill M.A., Yang J., Vogtenhuber C., Blazar B.R., Farrar M.A. IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells. JImmunol 2007, 178:280-290.
30. Lio C.W., Hsieh C.S. Atwo-step process for thymic regulatory T cell development. Immunity 2008, 28:100-111.
31. McCaughtry T.M., Etzensperger R., Alag A., Tai X., Kurtulus S., Park J.H., et al. Conditional deletion of cytokine receptor chains reveals that IL-7 and IL-15 specify CD8 cytotoxic lineage fate in the thymus. JExp Med 2012, 209:2263-2276.
32. Tai X., Erman B., Alag A., Mu J., Kimura M., Katz G., et al. Foxp3 transcription factor is proapoptotic and lethal to developing regulatory T cells unless counterbalanced by cytokine survival signals. Immunity 2013, 38:1116-1128.
33. Passerini L., Allan S.E., Battaglia M., Di Nunzio S., Alstad A.N., Levings M.K., et al. STAT5-signaling cytokines regulate the expression of FOXP3 in CD4+CD25+ regulatory T cells and CD4+CD25- effector T cells. Int Immunol 2008, 20:421-431.
34. Clark R.A., Kupper T.S. IL-15 and dermal fibroblasts induce proliferation of natural regulatory T cells isolated from human skin. Blood 2007, 109:194-202.
35. Zorn E., Nelson E.A., Mohseni M., Porcheray F., Kim H., Litsa D., et al. IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells invivo. Blood 2006, 108:1571-1579.
36. Bayer A.L., Pugliese A., Malek T.R. The IL-2/IL-2R system: from basic science to therapeutic applications to enhance immune regulation. Immunol Res 2013, 57:197-209.
37. Steel J.C., Waldmann T.A., Morris J.C. Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol Sci 2012, 33:35-41.
38. Mantel P.Y., Kuipers H., Boyman O., Rhyner C., Ouaked N., Ruckert B., et al. GATA3-driven Th2 responses inhibit TGF-beta1-induced FOXP3 expression and the formation of regulatory T cells. PLoS Biol 2007, 5:e329.
39. Battaglia A., Buzzonetti A., Baranello C., Fanelli M., Fossati M., Catzola V., et al. Interleukin-21 (IL-21) synergizes with IL-2 to enhance T-cell receptor-induced human T-cell proliferation and counteracts IL-2/transforming growth factor-beta-induced regulatory T-cell development. Immunology 2013, 139:109-120.
40. Cheng G., Yu A., Dee M.J., Malek T.R. IL-2R signaling is essential for functional maturation of regulatory T cells during thymic development. JImmunol 2013, 190:1567-1575.
41. Leclercq G., Debacker V., de Smedt M., Plum J. Differential effects of interleukin-15 and interleukin-2 on differentiation of bipotential T/natural killer progenitor cells. JExp Med 1996, 184:325-336.
42. Andersson J., Abrams J., Bjork L., Funa K., Litton M., Agren K., et al. Concomitant invivo production of 19 different cytokines in human tonsils. Immunology 1994, 83:16-24.
43. Yang-Snyder J.A., Rothenberg E.V. Spontaneous expression of interleukin-2 invivo in specific tissues of young mice. Dev Immunol 1998, 5:223-245.
44. Vaday G.G., Lider O. Extracellular matrix moieties, cytokines, and enzymes: dynamic effects on immune cell behavior and inflammation. JLeukoc Biol 2000, 67:149-159.
45. Yui M.A., Sharp L.L., Havran W.L., Rothenberg E.V. Preferential activation of an IL-2 regulatory sequence transgene in TCR gamma delta and NKT cells: subset-specific differences in IL-2 regulation. JImmunol 2004, 172:4691-4699.
46. Schneider R., Mohebiany A.N., Ifergan I., Beauseigle D., Duquette P., Prat A., et al. Bcell-derived IL-15 enhances CD8 T cell cytotoxicity and is increased in multiple sclerosis patients. JImmunol 2011, 187:4119-4128.
47. Ernestam S., af Klint E., Catrina A.I., Sundberg E., Engstrom M., Klareskog L., et al. Synovial expression of IL-15 in rheumatoid arthritis is not influenced by blockade of tumour necrosis factor. Arthritis Res Ther 2006, 8:R18.
48. Zong M., Loell I., Lindroos E., Nader G.A., Alexanderson H., Hallengren C.S., et al. Effects of immunosuppressive treatment on interleukin-15 and interleukin-15 receptor alpha expression in muscle tissue of patients with polymyositis or dermatomyositis. Ann Rheum Dis 2012, 71:1055-1063.
49. White A.J., Jenkinson W.E., Cowan J.E., Parnell S.M., Bacon A., Jones N.D., et al. An essential role for medullary thymic epithelial cells during the intrathymic development of invariant NKT cells. JImmunol 2014, 192:2659-2666.
50. Annunziato F., Cosmi L., Liotta F., Lazzeri E., Manetti R., Vanini V., et al. Phenotype, localization, and mechanism of suppression of CD4(+)CD25(+) human thymocytes. JExp Med 2002, 196:379-387.
51. Walters S.N., Webster K.E., Daley S., Grey S.T. Arole for intrathymic B cells in the generation of natural regulatory t cells. JImmunol 2014, 193:170-176.
52. Saadoun D., Rosenzwajg M., Joly F., Six A., Carrat F., Thibault V., et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. NEngl J Med 2011, 365:2067-2077.
53. Koreth J., Matsuoka K., Kim H.T., McDonough S.M., Bindra B., Alyea E.P., et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. NEngl J Med 2011, 365:2055-2066.
54. Hartemann A., Bensimon G., Payan C.A., Jacqueminet S., Bourron O., Nicolas N., et al. Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2013, 1:295-305.
55. Castela E., Le Duff F., Butori C., Ticchioni M., Hofman P., Bahadoran P., et al. Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata. JAMA Dermatol 2014, 150:748-751.